MURIEL BOWSER
MAYOR

NOV - 2 2016

The Honorable Phil Mendelson
Chairman
Council of the District of Columbia
John A. Wilson Building
1350 Pennsylvania Avenue, NW, Suite 504
Washington, DC 20004

Dear Chairman Mendelson:

In accordance with section 2 of the Confirmation Act of 1978, effective March 3, 1979, (D.C. Law 2-142; D.C. Official Code § 1-523.01 (2014 Repl. and 2016 Supp.)), and pursuant to section 12 of the Department of Forensic Sciences Establishment Act of 2011, approved August 17, 2011, (D.C. Law 19-18; D.C. Official Code § 5-1501.11), which established the Science Advisory Board ("Board"), I am pleased to nominate the following individual:

Namandje Bumpus, Ph.D.
2937 Fort Baker Drive, SE
Washington, D.C. 20020
(Ward 7)

for appointment as a scientist member of the Board, replacing Michael Coble, for a term to end April 18, 2019.

Enclosed you will find biographical information detailing the experience of the above-mentioned nominee, along with a proposed resolution to assist the Council during the confirmation process.

I would appreciate the Council's earliest consideration of this nomination for confirmation. Please do not hesitate to contact me or Steven Walker, Director, Mayor's Office of Talent and Appointments, should the Council require additional information.

Sincerely,

Muriel Bowser

Chairman Phil Mendelson
at the request of the Mayor

A PROPOSED RESOLUTION

IN THE COUNCIL OF THE DISTRICT OF COLUMBIA

Chairman Phil Mendelson, at the request of the Mayor, introduced the following resolution, which was referred to the Committee on _____.

To confirm the appointment of Dr. Namandje Bumpus to the Science Advisory Board.

RESOLVED, BY THE COUNCIL OF THE DISTRICT OF COLUMBIA, that this resolution may be cited as the "Science Advisory Board Dr. Namandje Bumpus Confirmation Resolution of 2016".

Sec. 2. The Council of the District of Columbia confirms the appointment of:

Namandje Bumpus, Ph.D.
2937 Fort Baker Drive, SE
Washington, D.C. 20020
(Ward 7)

as a scientist member of the Science Advisory Board, pursuant to section 2 of the Confirmation Act of 1993, effective October 15, (D.C. Law 10-39; D.C. Official Code § 1-523.01), and section 12 of the Department of Forensic Sciences Establishment Act of 2011, approved August 17, 2011, (D.C. Law 19-18; D.C. Official Code § 5-1501.11), which established the Science Advisory Board, replacing Michael Coble, for a term to end April 18, 2019.

Sec. 3. The Council of the District of Columbia shall transmit a copy of this resolution, upon its adoption, to the nominee and to the Office of the Mayor.

Sec. 4. This resolution shall take effect immediately.

Namandjé N. Bumpus, PhD

Dept. of Medicine – Division of Clinical Pharmacology
Johns Hopkins University School of Medicine
[redacted]
[redacted]

EDUCATION

1999 – 2003 Occidental College, Los Angeles, CA; B.A. in biology
2003 – 2008 University of Michigan, Ann Arbor, MI; Ph.D. in pharmacology (mentor: Dr. Paul F. Hollenberg)

POSTDOCTORAL TRAINING

2008 – 2010 The Scripps Research Institute, La Jolla, CA; Department of Molecular and Experimental Medicine (mentor: Dr. Eric F. Johnson)

ACADEMIC APPOINTMENTS

2010 – 2015 Assistant Professor, Department of Medicine – Division of Clinical Pharmacology and Department of Pharmacology & Molecular Sciences
Johns Hopkins University School of Medicine

2015 – Associate Professor, Department of Medicine – Division of Clinical Pharmacology and Department of Pharmacology & Molecular Sciences
Johns Hopkins University School of Medicine

ADMINISTRATIVE APPOINTMENTS

2015 – Associate Dean for Institutional and Student Equity (Joint appointment in the Office of Diversity and Inclusion and the Office for the Vice Dean for Education)
Johns Hopkins University School of Medicine

SCIENTIFIC ACTIVITIES

Editorial Activities

2013 – 2016 Editorial Board, *Drug Metabolism and Disposition*

Reviews articles on a regular basis for: *FEBS Letters; Food and Chemical Toxicology; Drug Metabolism and Disposition; International Journal of Nanotechnology; Medicinal Chemistry Communications; PLOS One; Journal of Pharmacology and Experimental Therapeutics; Biochemical Pharmacology; Xenobiotica; Pharmacogenomic; European Journal of Medicinal Chemistry; British Journal of Pharmacology; Journal of Endocrinology.*

Study Sections/Review Groups

2010 – AXA Research Fund, graduate/postdoctoral fellowship reviewer
2012 – 2013 Ad hoc member, NIH Xenobiotic and Nutrient Disposition and Action Study Section

2014 – 2020	Regular member, NIH Xenobiotic and Nutrient Disposition and Action Study Section
2014	Ad hoc member, NIDDK R13 conference grant review special emphasis panel
2015	Ad hoc member, NIDDK special emphasis panel reviewing ancillary studies to major ongoing clinical research studies to advance areas of scientific interest within the mission of the NIDDK (R01)
2015 –	Basic Pharmacology Advisory Committee (reviews graduate student fellowships, postdoctoral fellowships and research starter grants for junior faculty), Pharmaceutical Researchers and Manufacturers of America Foundation (PhRMA Foundation)
2015 –	Ad hoc reviewer, NSF, 2016 HBCU-UP Research Initiation Award

COMMITTEES AND ADMINISTRATIVE SERVICE

National

2008	American Society for Pharmacology and Experimental Therapeutics, Public Affairs Committee
2013	American Association of Pharmaceutical Scientists National Biotechnology Conference Abstract Reviewer
2013	American Association of Pharmaceutical Scientists, Drug Discovery and Development Interface Section, Membership Relations Committee
2013	American Association of Pharmaceutical Scientists Annual Meeting Abstract Reviewer
2013 – 2015	American Society for Pharmacology and Experimental Therapeutics, Drug Metabolism Division, Councilor
2014	Symposium Chair at Experimental Biology/ASPET Annual Meeting – *"Emerging Integrative Approaches to Predicting Host Response to Antimicrobials"*
2015 –	Basic Pharmacology Advisory Committee, Pharmaceutical Researchers and Manufacturers of America Foundation (PhRMA Foundation)
2016 – 2021	American Society for Pharmacology and Experimental Therapeutics, Drug Metabolism Division, Secretary/Treasurer (elect, present, past)

University of Michigan

2004 – 2005	Vice President, Association of Multicultural Scientists
2005 – 2006	President, Association of Multicultural Scientists

The Scripps Research Institute

2008 – 2010	Library Advisory Committee
2008 – 2010	Executive Board, Network for Women in Science
2008 – 2010	Career Development Chair, Society of Fellows

Johns Hopkins University School of Medicine

2010 – 2012	Department of Medicine's Task Force on Women's Academic Careers in Medicine

2013 – 2015	Summer Internship Program admissions committee
2013 –	Diversity Leadership Council
2014 –	MD/PhD Program/Admissions Committee
2014 –	Junior Faculty Resource Advisory Committee
2014 – 2015	Deputy to the Associate Dean for Graduate Biomedical Education
2015 –	Associate Dean for Institutional and Student Equity
2015	Co-chair, Baltimore City social enhancements task force
2016	Basic Science Investigation Task Force

AWARDS AND HONORS

2000	Andrew Mellon Undergraduate Research Fellowship
2002	Howard Hughes Medical Institute Undergraduate Research Fellowship
2003	NSF-Rackham Merit Fellowship, University of Michigan
2006	PhRMA Foundation Predoctoral Fellowship in Pharmacology/Toxicology
2008	UNCF/Merck Postdoctoral Fellowship
2009	Fletcher Jones Foundation – Training for Future Faculty Postdoctoral Fellowship
2011	PhRMA Foundation Research Starter Grant in Pharmacology/Toxicology
2014	Tanabe Young Investigator Award, American College of Clinical Pharmacology
2015	Drug Metabolism Early Career Achievement award, American Society for Pharmacology and Experimental Therapeutics
2015	Outstanding Alumnus/a Award, University of Michigan School of Medicine, Department of Pharmacology
2016	Presidential Early Career Award for Scientists and Engineers (Awarded by President Obama)

MEMBERSHIPS AND PARTICIPATION IN PROFESSIONAL SOCIEITIES

International Society for the Study of Xenobiotics
American Society for Pharmacology and Experimental Therapeutics,
- Public Affairs Committee, member (2008 – 2011)
- Councilor, Drug Metabolism Division (2013 – 2015)
- Symposium Chair at Experimental Biology/ASPET Annual Meeting (2014)
- Drug Metabolism Division, Secretary/Treasurer (2016 – 2021; elect, present, past)

American Society for Biochemistry and Molecular Biology
American Association of Pharmaceutical Scientists
- National Biotechnology Conference Abstract Reviewer (2013)
- Drug Discovery and Development Interface Section, Membership Relations Committee (2013 – 2014)
- Annual Meeting Abstract Reviewer (2013, 2014)

EXTRAMURAL FUNDING

Current

As principal investigator or project leader:

04/01/13 – 01/31/19 Cellular Signaling in Drug-Induced Toxicity
R01 GM103853
NIH
$1,140,000 total direct costs (current year: $190,000)
Role: PI, 30% effort

07/01/14 – 06/30/19 Tissue Pharmacology Imaging and Modeling
U19 AI113127 Sub-Project ID: 6596 (Program Project Grant)
NIH
$2,120,270 project total direct costs (current year: $427,583)
Role: Project Leader, 20% effort, component project of Development of Rectal Enema as Microbicide (DREAM; PI, Craig Hendrix)

As co-investigator:

07/19/13 – 06/30/18 The Effect of Depo-Provera on HIV Susceptibility, Immune Activation and PrEP PK
R01 AI110371
NIH
Total direct costs to Bumpus: $225,000 (current year: $45,000)
PI, Craig Hendrix
Role: Co-Investigator, performs drug metabolism analyses, 5% effort

01/01/14 – 11/30/20 Laboratory Center: HIV Prevention Trials Network
UM1 AI068613
NIH
Total direct costs to Bumpus: $800,000 (current year: $125,000)
PI, Susan Eshleman; Pharmacology Core PI, Craig Hendrix
Role: Director, drug metabolism and pharmacogenomics. Participates in HIV chemoprevention clinical trial design and performs drug metabolism analyses for completed studies, 30% effort.

01/01/14 – 11/30/20 Laboratory Center: Microbicide Trials Network
UM1 AI106707
NIH
Total direct costs to Bumpus: $182,000 (current year: $26,000)
PI, Charlene Dezzutti; Pharmacology Core PI, Craig Hendrix
Role: Co-Investigator. Participates in HIV chemoprevention clinical trial design and performs drug metabolism analyses for completed studies, 5% effort.

04/15/14 – 01/31/19 Eradicating Latent SIV from the CNS by CCR5 Inhibition
R01 NS089482
NIH
Total direct costs to Bumpus: $68,000 (current year: $14,000)
PI, Joseph Mankowski
Role: Co-Investigator. Performs mass spec-based analyses for macaque pharmacokinetics studies, 5% effort.

Previous:

01/01/11 – 12/31/11 Role of NNRTI Metabolites in Hepatotoxicity
Research Starter Grant in Pharmacology/Toxicology
PhRMA Foundation
$60,000 total direct costs
Role: PI, 20% effort

12/14/11 – 12/14/12 Reactive Metabolites in Hepatitis C Drug-Induced Hepatotoxicity
Roche
$60,000 total direct costs
Role: PI, 10% effort

01/01/11 – 06/30/13 Center for Novel Therapeutics for HIV-associated Cognitive Disorders
P30 MH075673
NIH
Total direct costs to Bumpus: salary support only
PI, Justin McArthur
Role: Co-Investigator, 10% effort.

10/01/11 – 12/31/13 Network Laboratory: HIV Prevention Treatment Network
UM1 AI068613
NIH
Total direct costs to Bumpus: $300,000
PI, Susan Eshleman; Pharmacology Core PI, Craig Hendrix
Role: Director, drug metabolism and pharmacogenomics. Participates in HIV chemoprevention clinical trial design and performs drug metabolism analyses for completed studies, 5% effort.

01/01/13 – 12/31/13 The Johns Hopkins Center for AIDS Research (JHU CFAR)
P30 AI094189
NIH
Total direct costs to Bumpus: $50,000
PI, Richard Chaisson and Chris Beyrer
Role: Faculty Development Award recipient, 10% effort.

08/01/12 – 05/31/13 Microbicide Trials Network – Pharmacology Core
UM1 AI968633
NIH
Total direct costs to Bumpus: $60,000
PI, Craig Hendrix
Role: Co-Investigator, 10% effort.

TEACHING ACTIVITIES

University of Michigan

2005 Nursing Pharmacology, Teaching Assistant

The Scripps Research Institute

2009 Instrumental Analysis, Instructor, University of San Diego
2010 Organic Chemistry II, Instructor, University of San Diego

Johns Hopkins University School of Medicine

2011 – Scientific Foundations of Medicine course, journal club preceptor for medical students, The Johns Hopkins University School of Medicine, Baltimore, MD
2012 – Graduate Pharmacology course, lecturer, "drug metabolism" lectures (2) to graduate students, The Johns Hopkins University School of Medicine, Baltimore, MD
2012 Mass Spectrometry in an "Omics" World course, lecturer, "metabolomics" lecture and "selected reaction monitoring" lecture to graduate students, The Johns Hopkins University School of Medicine, Baltimore, MD
2013 – Mechanisms in Bio-Organic Chemistry course, lecturer, "cytochrome P450" lecture to graduate students, The Johns Hopkins University School of Medicine, Baltimore, MD
2013 – Macromolecular Structure and Analysis course, lecturer, "mass spectrometry" lecture to graduate students, The Johns Hopkins University School of Medicine, Baltimore, MD
2013 – Intro to Research Ethics I for graduate students, discussion group leader, The Johns Hopkins University School of Medicine, Baltimore, MD
2013 – Biochemistry, Cellular and Molecular Biology Graduate Program, Proposal workshop leader, The Johns Hopkins University School of Medicine, Baltimore, MD
2013 – Scientific Foundations of Medicine course, lecturer, "drug metabolism" lectures (2) to medical students, The Johns Hopkins University School of Medicine, Baltimore, MD
2013 – Scientific Foundations of Medicine course, organizer and preceptor, drug metabolism small group discussion for medical students, The Johns Hopkins University School of Medicine, Baltimore, MD
2014 – Method and Logic course, discussion group leader, Biochemistry, Cellular and Molecular Biology Graduate Program, The Johns Hopkins University School of Medicine, Baltimore, MD

MENTORING

Advisees, junior faculty

Sandy Hwang Fang, MD, FACS, Assistant Professor, Director, High-Resolution Anoscopy Clinic Ravitch Division, Colon and Rectal Surgery, Department of Surgery, 2016 –

Advisees, post-doctoral

Lindsay Avery, PhD, 2012 – 2014
Projects: Anatomic distribution of efavirenz metabolites in human subjects; activation of AMP-activated protein kinase by valproic acid metabolites.
Awards: 1st place in the postdoctoral fellow best abstract competition, ASPET Division of Drug Metabolism at *Experimental Biology 2013*, Boston, MA
Current position: Senior Scientist, Biologics Drug Disposition, Pfizer – Department of Pharmacokinetics, Pharmacodynamics & Metabolism, Cambridge, MA

Advisees, pre-doctoral

Elizabeth Hersman (PhD in pharmacology completed December 2013)
Thesis title: "Sensitive and Specific Proteomic Identification and Quantitation of Murine Cytochrome P450 Enzymes and Histone Post-Translational Modifications Using Mass Spectrometry"
Current position: Scientist, Mass Spectrometry Division, Thermo Scientific.

Yanhui Lui (PhD in pharmacology completed March 2014)
Thesis title: "Cytochrome P450 3A-mediated Pharmacokinetic Variations for Anti-infective Agents"
Awards: 3rd place in the graduate student best abstract competition in the ASPET Division of Drug Metabolism at *Experimental Biology 2012*, San Diego, CA; Bae Gyo Jung Award, Johns Hopkins Young Investigators' Day 2014
Current position: Senior Scientist, Department of Pharmacokinetics, Pharmacodynamics & Metabolism, Merck, Kenilworth, NJ.

Elaine To (PhD in pharmacology completed June 2014)
Thesis title: "Metabolism of Antiretroviral Drugs Used in HIV Pre-Exposure Prophylaxis"
Current position: Senior Scientist, InCube Labs, San Jose, CA

Julie Lade (2013 –), doctoral candidate in pharmacology
Project: Activation of nuclear receptors by anti-HIV drug metabolites
Awards: 2015 PhRMA Foundation Graduate Fellowship in Pharmacology/Toxicology;
1st place in the graduate student best abstract competition, ASPET Division of Drug Metabolism at *Experimental Biology 2015*, Boston, MA
1st place in the graduate student best abstract competition, ASPET Division of Drug Metabolism at *Experimental Biology 2016*, San Diego, CA

Philip Cox (2013 –), doctoral candidate in the Biochemistry, Cellular and Molecular Biology graduate program
Project: Molecular basis for cytochrome P450 2B6 activity towards the anti-HIV drug efavirenz
Awards: 2013 NSF graduate student fellowship

Dominique Figueroa (2014 –), doctoral candidate in pharmacology
Project: Tissue- and cell-specific activation of the nucleotide reverse transcriptase inhibitor tenofovir by nucleotide kinases

Carley Heck (2015 –), pre-doctoral student in pharmacology
Project: Activation of the IRE1alpha pathway by non-nucleotide reverse transcriptase Inhibitors
Awards: 2016 NSF graduate student fellowship

Advisees, master's degree

Lindsay Yanakakis (MS in biology completed in May 2012)
Thesis title: "In Vitro Metabolism of the Anti-HIV Drug Etravirine"

Current position: Molecular Genetics Technician at Northwestern Reproductive Genetics, Chicago, IL

Jennifer VanAusdall (MS in pharmacology completed in August 2013)
Thesis title: "Activation of Pro-apoptotic Pathways by Efavirenz Metabolites"
Current position: Tenure-track chemistry teacher, Frederick Douglass High School, Baltimore, MD.

Advisees, post-baccalaureate

Toussaint Jordan (2011 – 2012). Subsequently earned a MS in chemistry at Farleigh-Dickinson University
Current position: Product Development Chemist and TRI-K Industries, Denville, NJ.

Advisees, undergraduate

Laura Dankovich (2010), Dept. of Biology, Johns Hopkins University.
Christiana Obeng (2012 – 2013), Dept. of Biology, Johns Hopkins University.
Jennifer Nguyen (2014), Dept. of Biochemistry, Mercer University
Errol Hunte (2015), Dept. of Chemistry, City University of New York - Brooklyn

EXTRAMURAL INVITED PRESENTATIONS

1. "Drug Metabolism by P450 2B6 and the Naturally Occurring K262R Mutant of P450 2B6." Occidental College, Los Angeles, CA. November 2, 2005.

2. "Investigation of the Effects of the Naturally Occurring K262R Mutation in P450 2B6 on Active Site Structure and Function." *4th Annual Merck Drug Metabolism Graduate Research Symposium.* Merck Research Laboratories, West Point, PA. June 19, 2006.

3. "Regulation of P450s Involved in Lipid Metabolism." The University of Sydney, Sydney, NSW, Australia. February 23, 2009.

4. "Regulation of Cyp4a31 by AMP-activated Protein Kinase and Peroxisome Proliferator Activated Receptor Alpha." *Experimental Biology 2010.* Anaheim, CA. April 26, 2010.

5. "Metabolism of Efavirenz by the Cytochromes P450." Merck Research Laboratories, West Point, PA. June 21, 2010.

6. "Women in Pharmacology Panel." *Experimental Biology* 2011. Washington, DC. April 12, 2011.

7. "Pharmacologic Mechanisms of Antiretroviral Toxicity." Plenary speaker, *7th Annual Course in Clinical Pharmacology*, Turin, Italy. January 13, 2012.

8. "Biotransformation of Antiretroviral Drugs in Liver Toxicity." Plenary speaker, *Antiviral Pharmacology Workshop*, Barcelona, Spain. November 2, 2012.

9. "Pharmacogenomic Determinants For HIV PrEP." Plenary speaker, *HIV Prevention Trials Network Annual Meeting.* Washington, DC. May 07, 2013.

10. "Pharmacological Approaches to HIV Prevention." Keynote Speaker, Department of Pharmacology Annual Retreat, University of Michigan School of Medicine, Ann Arbor, MI. August 28, 2013.

11. "Drug-Induced Toxicities During HIV Pre-Exposure Prophylaxis." Michigan State University School of Medicine, Department of Pharmacology & Toxicology, East Lansing, MI. August 29, 2013.

12. "Cellular Signaling and Antiretroviral Drug Toxicity." University of Washington School of Pharmacy, Departments of Medicinal Chemistry and Pharmaceutics, Seattle, WA. January 23, 2014.

13. "Activation of JNK-BimEL Signaling by Anti-HIV Drug Metabolites." *Great Lakes Drug Metabolism and Disposition Annual Meeting*. Indianapolis, IN. May 15, 2014.

14. "New Insights into the Control of Tenofovir Activation." Plenary speaker, *HIV Prevention Trials Network Annual Meeting*. Arlington, VA. June 17, 2014.

15. "Impact of CYP3A5 Genotype on Maraviroc Pharmacokinetics." Award Lecture, *American College of Clinical Pharmacology Annual Meeting*. Atlanta, GA. September 15, 2014.

16. "Activation of JNK and BimEL Signaling in Anti-HIV Drug-Induced Toxicity." Emory University School of Medicine, Department of Pharmacology, Atlanta, GA. September 16, 2014.

17. "Metabolism and Pharmacogenetic Considerations for the Anti-HIV Drug Maraviroc." Keynote Speaker, Princeton Area American Chemical Society Meeting, Princeton University, Princeton, NJ. December 16, 2014.

18. "Impact of Cytochrome P450 Activity on anti-HIV Drug Exposure." University of Maryland School of Pharmacy, Department of Pharmaceutical Science Baltimore, MD. March 4, 2015.

19. "Drug Metabolism Considerations in HIV Treatment and Prevention." Award Lecture, *Experimental Biology 2015/ASPET Annual Meeting*, Boston, MA. March 30, 2015.

20. "Newer Pharmacokinetics Techniques in HIV Pre-exposure Prophylaxis Trials." Plenary speaker, *Mucosal Assays Meeting*, Arlington, VA. August 26, 2015.

21. "Drug Metabolism in HIV Prevention." Outstanding Alumnus/a Award Lecture, University of Michigan School of Medicine, Department of Pharmacology, Ann Arbor, MI. September 25, 2015.

22. "Using Drug Metabolism Insights to Predict Drug Induced Toxicities." Plenary Speaker. New Jersey American Chemical Society Drug Metabolism Discussion Group Symposium, Somerset, NJ. October 15, 2015.

23. "Drug-Induced Toxicity Mediated by Drug Metabolites." University of Pittsburgh School of Pharmacy, Department of Pharmaceutical Sciences, Pittsburgh, PA. November 17, 2015.

PEER-REVIEWED PUBLICATIONS

1. Harleton E, Webster M, **Bumpus NN**, Kent UM, Rae JM and Hollenberg PF. Metabolism of N,N',N"-Triethylenethiophosphoramide by CYP 2B1 and CYP2B6 results in the inactivation of both isoforms by two distinct mechanisms. *Journal of Pharmacology and Experimental Therapeutics.* 2004; 310(3):1011-1019.

2. **Bumpus NN**, Sridar C, Kent UM and Hollenberg PF. The Naturally occurring K262R mutant of P450 2B6 exhibits alterations in substrate metabolism and inactivation. *Drug Metabolism and Disposition.* 2005; 33(6):795-802.

3. **Bumpus NN**, Kent UM and Hollenberg PF. Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms. *Journal of Pharmacology and Experimental Therapeutics.* 2006; 318(1):345-351.

4. Hollenberg PF, Kent UM and **Bumpus NN**. Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications. *Chemical Research in Toxicology.* 2008; 21(1):189-205.

5. **Bumpus NN** and Hollenberg PF. Investigation of the mechanisms underlying the effects of the K262R mutation of P450 2B6 on catalytic activity. *Molecular Pharmacology.* 2008; 74(4):990-9.

6. **Bumpus NN** and Hollenberg PF. Cross-linking of cytochrome P450 2B6 to NADPH-cytochrome P450 reductase: identification of a potential site of interaction. *Journal of Inorganic Biochemistry.* 2010; 104(4):485-8.

7. **Bumpus NN** and Johnson EF. 5-Aminoimidazole-4-carboxyamide-ribonucleoside (AICAR)-stimulated hepatic expression of Cyp4a10, Cyp4a14, Cyp4a31, and other peroxisome proliferator-activated receptor α-responsive mouse genes is AICAR 5'-monophosphate-dependent and AMP-activated protein kinase-independent. *Journal of Pharmacology and Experimental Therapeutics.* 2011; 339(3):886-95.

8. **Bumpus NN.** Efavirenz and 8-hydroxyefavirenz induce cell death via a JNK- and BimEL-dependent mechanism in primary human hepatocytes. *Toxicology and Applied Pharmacology.* 2011; 257(2):227-34.

9. Yanakakis LJ and **Bumpus NN**. Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping and characterization of autoinduction of cytochrome P450-dependent metabolism. *Drug Metabolism and Disposition.* 2012; 40(4):803-14.

10. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kakia A, Odoyo J, Mucunguzi A, Nakku-Joloba E, Twesigye R, Ngure K, Apaka C, Tamooh H, Gabona F, Mujugira A, Panteleeff D, Thomas KK, Kidoguchi L, Krows M, Revall J, Morrison S, Haugen H, Emmanuel-Ogier M, Ondrejcek L, Coombs RW, Frenkel L, Hendrix C, **Bumpus NN,** Bangsberg D, Haberer JE, Stevens WS, Lingappa JR, Celum C. Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women. *New England Journal of Medicine.* 2012; 367(5):399-410.

11. Lu Y, Hendrix CW and **Bumpus NN**. Cytochrome P450 3A5 Plays a Prominent Role in the Oxidative Metabolism of the Anti-HIV Drug Maraviroc. *Drug Metabolism and Disposition.* 2012; 40(12):2221-30.

12. Anton PA, Cranston RD, Kashuba A, Hendrix C, **Bumpus NN**, Richardson-Harman N, Elliott J, Janocko L, Khanukhova E, Dennis RA, Cumberland WG, Ju C, Carballo-Diéguez A, Mauck C, McGowan IM. RMP-02/MTN-006: A Phase 1 Rectal Safety, Acceptability, Pharmacokinetic and Pharmacodynamic Study of Tenofovir 1% Gel Compared to Oral Tenofovir Disoproxil Fumerate. *AIDS Research and Human Retroviruses.* 2012; 28(11):1412-21.

13. Tovar-Y-Romo LB, **Bumpus NN**, Pomerantz D, Avery LB, Sacktor N, McArthur JC, Haughey NJ. Dendritic spine injury induced by the 8-hydroxy metabolite of Efavirenz. *Journal of Pharmacology and Experimental Therapeutics.* 2012; 343(3):696-703.

14. Avery LB, VanAusdall JL, Hendrix CW, and **Bumpus NN**. Compartmentalization and Antiviral Effect of Efavirenz Metabolites in Blood Plasma, Seminal Plasma and Cerebrospinal Fluid. *Drug Metabolism and Disposition.* 2012; 41(2):422-9.

15. Hendrix C, Chen BA, Guddera V, Hoesley C, Justman J, Nakabiito C, Salata R, Soto-Torres L, Patterson K, Minnis AA, Gandham S, Gomez K, Richardson BA and **Bumpus NN**. MTN-001: Randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. *PLoS One.* 2013; 8(1):e55013.

16. Fogel JM, Wang L, Parsons TL, Ou SS, Piwowar-Manning E, Chen Y, Mudhune VO, Hosseinipour MC, Kumwenda J, Hakim JG, Chariyalertsak S, Panchia R, Sanne I, Kumarasamy N, Grinsztejn B, Makhema J, Pilotto J, Santos BR, Mayer KH, McCauley M, Gamble T, **Bumpus NN**, Hendrix CW, Cohen MS, Eshleman SH. Undisclosed antiretroviral drug use in a multi-national clinical trial (HPTN 052). *Journal of Infectious Diseases.*2013; 208(10):1624-8

17. Lade JM, Avery LB, **Bumpus NN**. Human Biotransformation of the Non-nucleoside Reverse Transcriptase Inhibitor Rilpivirine and a Cross Species Metabolism Comparison. *Antimicrobial Agents and Chemotherapy.* 2013; 57(10):5067-79.

18. To EE, Hendrix CW, **Bumpus NN**. Dissimilarities in the Metabolism of Antiretroviral Drugs used in HIV Pre-exposure Prophylaxis in Colon and Vagina Tissues. *Biochemical Pharmacology.* 2013; 86(7):979-90.

19. Avery LB and **Bumpus NN**. Valproic Acid is a Novel Activator of AMP-Activated Protein Kinase and Decreases Liver Mass, Hepatic Fat Accumulation, and Serum Glucose in Obese Mice. *Molecular Pharmacology.* 2014; 85(1):1-10.

20. Spivak AM, Andrade A, Eisele E, Hoh R, Bacchetti P, **Bumpus NN**, Emad F, Buckheit R 3rd, McCance-Katz EF, Lai J, Kennedy M, Chander G, Siliciano RF, Siliciano JD, Deeks SG. A Pilot Study Assessing the Safety and Latency Reversing Activity of Disulfiram in HIV-1-Infected Adults on Antiretroviral Therapy. *Clinical Infectious Disease.* 2014; 58(6):883-90.

21. Hersman EM and **Bumpus NN**. A Targeted Proteomics Approach for Profiling Murine Cytochrome P450 Expression. *Journal of Pharmacology and Experimental Therapeutics.* 2014; 349(2):221-8.

22. Donnell D, Baeten JM, **Bumpus NN**, Brantley J, Bangsberg DR, Haberer JE, Mujugira A, Mugo N, Ndase P, Hendrix C and Celum C. HIV Protective Efficacy and Correlates of Tenofovir Blood Concentrations in a Clinical Trial of PrEP for HIV Prevention. *Journal of Acquired Immune Deficiency Syndrome*. 2014; 66(3):340-8.

23. Seamon KJ, Hansen EC, Kadina AP, Kashemirov BA, McKenna CE, **Bumpus NN** and Stivers JT. Small Molecule Inhibition of SAMHD1 dNTPase by Tetramer Destabilization. *Journal of the American Chemical Society*. 2014; 136(28):9822-5.

24. Lu Y, Fuchs EJ, Hendrix CW and **Bumpus NN**. Cytochrome P450 3A5 Genotype Impacts Maraviroc Concentrations in Healthy Volunteers. *Drug Metabolism and Disposition*. 2014; 42(11):1796-802.

25. Cox P and **Bumpus NN**. Structure-activity studies reveal the oxazinone ring is a determinant of cytochrome P450 2B6 activity towards efavirenz. *ACS Medicinal Chemistry Letters*. 2014; 5(10):1156-1161.

26. Yang K-H, Hendrix C, **Bumpus N**, Elliott J, Tanner K , Mauck C, Cranston R, McGowan I, Richardson-Harman N, Anton PA and Kashuba AD. A Multi-Compartment Single and Multiple Dose Pharmacokinetic Comparison of Rectally Applied Tenofovir 1% Gel and Oral Tenofovir Disoproxil Fumarate. *PLOS One*. 2014; 9(10):e106196.

27. Richardson-Harman N, Hendrix CW, **Bumpus NN**, Mauck C, Cranston RD, Yang K, Elliott J, Tanner K, McGowan I, Kashuba A and Anton PA. Correlation between Compartmental Tenofovir Concentrations and an Ex Vivo Rectal Biopsy Model of Tissue Infectibility in the RMP-02/MTN-006 Phase 1 Study. *PLoS One*. 2014; 9(10):e111507.

28. Lade JM, To EE, Hendrix CW and **Bumpus NN**. Discovery of Genetic Variants of the Kinases that Activate Tenofovir in a Compartment-Specific Manner. *EBioMedicine*. 2015; 2(9):1145–1152.

29. Elliott JH, McMahon JH, Chang CC, Lee SA, Hartogensis W, **Bumpus N**, Savic R, Roney J, Hoh R, Solomon A, Piatak M, Gorelick RJ, Lifson J, Bacchetti P, Deeks SG and Lewin SR. Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. *Lancet HIV*. 2015; 2(12):e520-9.

30. Hendrix CW, Andrade A, **Bumpus NN**, Kashuba A, Marzinke MA, Moore A, Anderson PL, Bushman LR, Fuchs EJ, Wiggins I, Radebaugh C, Prince H, Bakshi RP, Wang R, Richardson P, Shieh E, McKinstry L, Li X, Donnell D, ElHarrar V, Mayer KH and Patterson K. Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine after Directly Observed Dosing in Healthy Volunteers to establish Adherence Benchmarks (HPTN 066). *AIDS Research and Human Retroviruses*. 2016; 32(1):32-43.

31. Shim JS, Li RJ, **Bumpus N**, Head S, Pasunooti K, Yang EJ, Lv J, Shi W and Liu JO. Divergence of Anti-angiogenic Activity and Hepatotoxicity of Different Stereoisomers of Itraconazole. *Accepted to Clinical Cancer Research*.

PATENTS

1. Namandjé Bumpus and Lindsay Avery: Compounds & Methods to Decrease Obesity-related Hepatic Fat Accumulation & Serum Glucose; US Patent application no. 14/637,784; filed 03/04/15; pending.

Executive Office of the Mayor - Office of Talent and Appointments
John A. Wilson Building | 1350 Pennsylvania Avenue, Suite 600 | Washington, DC 20004

Namandjé N. Bumpus, Ph.D.

Dr. Namandjé N. Bumpus is an associate professor of medicine, pharmacology, and molecular sciences at the Johns Hopkins University School of Medicine in Baltimore, Maryland.

Dr. Bumpus's research combines biochemical, molecular, genetic and pharmacological approaches in efforts to gain a mechanistic understanding of inter-individual differences in HIV drug efficacy and toxicity, with the goal of developing efficacious drugs for HIV prevention. Dr. Bumpus has authored or co-authored numerous peer-reviewed publications and serves on the editorial board of the journal *Drug Metabolism and Disposition*. She is also a regular member of the NIH Xenobiotic and Nutrient Disposition and Action study section. She has been honored with several prestigious scientific awards including the Tanabe Young Investigator Award from the American College of Clinical Pharmacology, the Drug Metabolism Early Career Award from the American Society for Pharmacology and Experimental Therapeutics, the Leon I. Goldberg Award from the American Society for Clinical Pharmacology and Therapeutics, and the Presidential Early Career Award for Scientists and Engineers awarded by President Obama.

A Ward 7 resident, Dr. Bumpus received a Ph.D. in pharmacology at the University of Michigan-Ann Arbor. She completed a postdoctoral fellowship in biochemistry and molecular medicine at the Scripps Research Institute in La Jolla, California.

GOVERNMENT OF THE DISTRICT OF COLUMBIA
Executive Office of Mayor Muriel Bowser

Office of the General Counsel to the Mayor

To: Lauren C. Vaughan, Steve Walker
From: Betsy Cavendish
Date: October 26, 2016
Subject: Legal sufficiency review of Resolutions nominating Dr. Namandje Bumpus, Dr. Marie Fidelia-Lambert, and Dr. Jeanne Jordan as scientist members of the Science Advisory Board

---

This is to Certify that this office has reviewed the above-referenced Resolutions and found them to be legally unobjectionable. If you have any questions in this regard, please do not hesitate to call me at 202-724-7681.

Elizabeth A. Cavendish

Elizabeth Cavendish